Approved but non-funded vaccines: accessing individual protection.

Abstract:

:Funded immunization programs are best able to achieve high participation rates, optimal protection of the target population, and indirect protection of others. However, in many countries public funding of approved vaccines can be substantially delayed, limited to a portion of the at-risk population or denied altogether. In these situations, unfunded vaccines are often inaccessible to individuals at risk, allowing potentially avoidable morbidity and mortality to continue to occur. We contend that private access to approved but unfunded vaccines should be reconsidered and encouraged, with recognition that individuals have a prerogative to take advantage of a vaccine of potential benefit to them whether it is publicly funded or not. Moreover, numbers of "approved but unfunded" vaccines are likely to grow because governments will not be able to fund all future vaccines of potential benefit to some citizens. New strategies are needed to better use unfunded vaccines even though the net benefits will fall short of those of funded programs. Canada, after recent delays funding several new vaccine programs, has developed means to encourage private vaccine use. Physicians are required to inform relevant patients about risks and benefits of all recommended vaccines, publicly funded or not. Likewise, some provincial public health departments now recommend and promote both funded and unfunded vaccines. Pharmacists are key players in making unfunded vaccines locally available. Professional organizations are contributing to public and provider education about unfunded vaccines (e.g. herpes zoster, not funded in any province). Vaccine companies are gaining expertise with direct-to-consumer advertising. However, major challenges remain, such as making unfunded vaccines more available to low-income families and overcoming public expectations that all vaccines will be provided cost-free, when many other recommended personal preventive measures are user-pay. The greatest need is to change the widespread perception that approved vaccines should be publicly funded or ignored.

journal_name

Vaccine

journal_title

Vaccine

authors

Scheifele DW,Ward BJ,Halperin SA,McNeil SA,Crowcroft NS,Bjornson G

doi

10.1016/j.vaccine.2013.12.027

subject

Has Abstract

pub_date

2014-02-07 00:00:00

pages

766-70

issue

7

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(13)01758-1

journal_volume

32

pub_type

杂志文章,评审

相关文献

VACCINE文献大全
  • Humoral and cellular immunity induced by antigens adjuvanted with colloidal iron hydroxide.

    abstract::The immunopotentiating activities of colloidal iron hydroxide, a novel, experimental mineral adjuvant, and of aluminium hydroxide. the licensed adjuvant for human vaccines, were compared. Our studies revealed that colloidal iron hydroxide and aluminium hydroxide behaved comparably with respect to supporting induction ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(98)00201-1

    authors: Leibl H,Tomasits R,Brühl P,Kerschbaum A,Eibl MM,Mannhalter JW

    更新日期:1999-03-05 00:00:00

  • Antibody persistence following booster vaccination against tick-borne encephalitis: 3-year post-booster follow-up.

    abstract::In order to evaluate the long-term immunity 2 and 3 years after booster vaccination against tick-borne encephalitis (TBE) following time intervals 3 years and longer since last TBE immunization, 195 (mean age 50.5+/-15.1 years) and 240 subjects (mean age 47.0+/-15.4 years), respectively, who had received a single boos...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2007.01.116

    authors: Rendi-Wagner P,Paulke-Korinek M,Kundi M,Wiedermann U,Laaber B,Kollaritsch H

    更新日期:2007-06-28 00:00:00

  • Potent adaptive immune responses induced against HIV-1 gp140 and influenza virus HA by a polyanionic carbomer.

    abstract::Carbopol is a polyanionic carbomer gel used in man for a variety of topical applications and drug delivery purposes. Here we show that subcutaneous administration of carbopol with glycoprotein antigens elicits unusually strong specific adaptive immune responses in mice. Recombinant soluble HIV-1 envelope glycoprotein ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.01.046

    authors: Krashias G,Simon AK,Wegmann F,Kok WL,Ho LP,Stevens D,Skehel J,Heeney JL,Moghaddam AE,Sattentau QJ

    更新日期:2010-03-16 00:00:00

  • Intranasal vaccination of infant mice induces protective immunity in the absence of nasal-associated lymphoid tissue.

    abstract::Intranasal (i.n.) immunization is an effective regimen for the prophylaxis of respiratory diseases in early life. The aim of this study was to assess the need for nasal-associated lymphoid tissue (NALT) and cervical lymph nodes (CLN) in induction of protective immunity following mucosal vaccination of infant mice. We ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2008.01.027

    authors: Sabirov A,Metzger DW

    更新日期:2008-03-17 00:00:00

  • Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates.

    abstract::The new intradermal DNA delivery technique, termed DNA tattooing might overcome the discrepancy between the encouraging immunogenicity results obtained with DNA vaccines in murine studies and the poor results obtained in non-human primates and humans, the so called "simian barrier". Here, we demonstrate a 10- to 100-f...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2008.03.091

    authors: Verstrepen BE,Bins AD,Rollier CS,Mooij P,Koopman G,Sheppard NC,Sattentau Q,Wagner R,Wolf H,Schumacher TN,Heeney JL,Haanen JB

    更新日期:2008-06-19 00:00:00

  • Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents.

    abstract:OBJECTIVE:In response to the emergence of influenza viruses with pandemic potential, we evaluated a swine-origin influenza A/H3N2 variant (H3N2v) vaccine in children. STUDY DESIGN:This multicenter phase II open-label study assessed the safety and immunogenicity of two doses, 21 days apart, of investigational unadjuvan...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2019.07.085

    authors: Munoz FM,Anderson EJ,Bernstein DI,Harrison CJ,Pahud B,Anderson E,Creech CB,Berry AA,Kotloff KL,Walter EB,Atmar RL,Bellamy AR,Chang S,Keitel WA

    更新日期:2019-08-23 00:00:00

  • Post-licensure rapid immunization safety monitoring program (PRISM) data characterization.

    abstract:BACKGROUND:The Post-Licensure Rapid Immunization Safety Monitoring (PRISM) program is the immunization safety monitoring component of FDA's Mini-Sentinel project, a program to actively monitor the safety of medical products using electronic health information. FDA sought to assess the surveillance capabilities of this ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2013.04.088

    authors: Baker MA,Nguyen M,Cole DV,Lee GM,Lieu TA

    更新日期:2013-12-30 00:00:00

  • Development of an ex vivo human skin model for intradermal vaccination: tissue viability and Langerhans cell behaviour.

    abstract::The presence of resident Langerhans cells (LCs) in the epidermis makes the skin an attractive target for DNA vaccination. However, reliable animal models for cutaneous vaccination studies are limited. We demonstrate an ex vivo human skin model for cutaneous DNA vaccination which can potentially bridge the gap between ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.07.088

    authors: Ng KW,Pearton M,Coulman S,Anstey A,Gateley C,Morrissey A,Allender C,Birchall J

    更新日期:2009-10-09 00:00:00

  • Influenza vaccination among U.S. pediatric patients receiving care from federally funded health centers.

    abstract:INTRODUCTION:During the 2018-2019 influenza season, vaccination coverage among U.S. children was 62.6%. The purpose of this study was to estimate the prevalence of influenza vaccinations among pediatric patients seen in U.S. health centers, and to explore potential disparities in vaccination coverage among subpopulatio...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2020.07.021

    authors: Lebrun-Harris LA,Mendel Van Alstyne JA,Sripipatana A

    更新日期:2020-09-03 00:00:00

  • Neutralization epitopes on the antigenic domain II of the Orientia tsutsugamushi 56-kDa protein revealed by monoclonal antibodies.

    abstract::Monoclonal antibodies (MoAbs) reactive with the authentic Orientia tsutsugamushi 56-kDa protein were generated. MoAb FS10 and FS15 showed in vitro, as well as, in vivo neutralizing activity upon O. tsutsugamushi infection. Deletion mutants of the gene for 56-kDa protein of O. tsutsugamushi Boryong were expressed to ma...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(00)00167-5

    authors: Seong SY,Kim MK,Lee SM,Odgerel Z,Choi MS,Han TH,Kim IS,Kang JS,Lim BU

    更新日期:2000-08-15 00:00:00

  • Capacity for a global vaccine safety system: the perspective of national regulatory authorities.

    abstract::Confidence in vaccine safety is critical to national immunization strategies and to global public health. To meet the Millenium Development Goals, and buoyed by the success of new vaccines produced in developing countries, the World Health Organization has been developing a strategy to establish a global system for ef...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.05.045

    authors: Graham JE,Borda-Rodriguez A,Huzair F,Zinck E

    更新日期:2012-07-13 00:00:00

  • A respiratory syncytial virus (RSV) vaccine based on parainfluenza virus 5 (PIV5).

    abstract::Human respiratory syncytial virus (RSV) is a leading cause of severe respiratory disease and hospitalizations in infants and young children. It also causes significant morbidity and mortality in elderly and immune compromised individuals. No licensed vaccine currently exists. Parainfluenza virus 5 (PIV5) is a paramyxo...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.03.049

    authors: Phan SI,Chen Z,Xu P,Li Z,Gao X,Foster SL,Teng MN,Tripp RA,Sakamoto K,He B

    更新日期:2014-05-23 00:00:00

  • Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells.

    abstract::We compared the effects of yeast-treated human dendritic cells (DCs) with CD40L-matured human DCs for the induction of effector cells and the number and functionality of CD4(+)CD25(+)CD127(-)FoxP3(+) regulatory T cells (Tregs). DCs were treated with yeast or CD40L and cocultured with isolated autologous CD4(+) T cells...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.04.101

    authors: Cereda V,Vergati M,Huen NY,di Bari MG,Jochems C,Intrivici C,Gulley JL,Apelian D,Schlom J,Tsang KY

    更新日期:2011-07-12 00:00:00

  • BBG2Na an RSV subunit vaccine candidate intramuscularly injected to human confers protection against viral challenge after nasal immunization in mice.

    abstract::Respiratory syncytial virus (RSV) is a major respiratory pathogen responsible for severe pulmonary disease. We have developed a parenterally administered vaccine, BBG2Na, which is currently in a phase III clinical trial. BBG2Na comprises residues 130--230 of RSV-A G protein (G2Na) fused to the BB carrier protein. In t...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(01)00105-0

    authors: Goetsch L,Plotnicky-Gilquin H,Aubry JP,De-Lys P,Haeuw JF,Bonnefoy JY,Nguyen NT,Corvaïa N,Velin D

    更新日期:2001-07-16 00:00:00

  • Rectal immunization of mice with hepatitis A vaccine induces stronger systemic and local immune responses than parenteral immunization.

    abstract::Systemic (spleen cell (SPLC), serum antibodies) and intestinal mucosal (Peyer's patch cells (PPC), lamina propria lymphocytes (LPLs), coproantibodies) immune responses were compared in mice immunized with varying doses (144, 72, 36, 18 ELISA units [EU]) of HAVRIX, an alum-adsorbed killed hepatitis A virus (HAV) vaccin...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(02)00699-0

    authors: Mitchell LA,Galun E

    更新日期:2003-03-28 00:00:00

  • Evidence supporting the hypothesis that specifically modifying a malaria peptide to fit into HLA-DRbeta1*03 molecules induces antibody production and protection.

    abstract::EBA-175 protein is used as ligand in Plasmodium falciparum binding to erythrocytes. Evidence shows that conserved peptide 1815 from this protein having high red blood cell binding ability plays an important role in the invasion process. This peptide is neither immunogenic nor protective. Residues were substituted by a...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2004.08.052

    authors: Cifuentes G,Salazar LM,Vargas LE,Parra CA,Vanegas M,Cortes J,Patarroyo ME

    更新日期:2005-02-18 00:00:00

  • One-year study of the 2-1-1 intramuscular postexposure rabies vaccine regimen in 100 severely exposed Thai patients using rabies immune globulin and Vero cell rabies vaccine.

    abstract::The 2-1-1 rabies postexposure treatment schedule is an abbreviated regimen in which a tissue culture rabies vaccine is administered intramuscularly at two sites on day 0, and at one site on days 7 and 21. Compared to the standard five-dose intramuscular regimen, the 2-1-1 schedule reduces the number of clinic visits f...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(91)90244-z

    authors: Chutivongse S,Wilde H,Fishbein DB,Baer GM,Hemachudha T

    更新日期:1991-08-01 00:00:00

  • Decline of varicella vaccination in German surveillance regions after recommendation of separate first-dose vaccination for varicella and measles-mumps-rubella.

    abstract:BACKGROUND:Germany introduced routine varicella (V) vaccination in 2004. Due to a slightly increased risk of febrile convulsions after first-dose application of combined measles-mumps-rubella-varicella (MMRV) vaccine separate first-dose vaccinations with MMR and monovalent V vaccine were recommended in September 2011. ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2013.12.065

    authors: Streng A,Liese JG

    更新日期:2014-02-12 00:00:00

  • A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis.

    abstract::Human papillomaviruses (HPV), particularly HPV16, is considered a necessary cause of cervical and oral cancer. Thus, the development of a therapeutic vaccine against HPV is important for the control of cervical cancer. However, therapeutic vaccination has been limited by inadequate antigen-specific immune responses. H...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2007.12.034

    authors: Liu B,Ye D,Song X,Zhao X,Yi L,Song J,Zhang Z,Zhao Q

    更新日期:2008-03-04 00:00:00

  • Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty.

    abstract:BACKGROUND:A randomized trial demonstrated that a high-dose inactivated influenza vaccine (IIV-HD) was 24.2% more efficacious than a standard-dose vaccine (IIV-SD) against laboratory-confirmed influenza illness in adults ≥65 years. To evaluate the consistency of IIV-HD benefits, supplemental analyses explored efficacy ...

    journal_title:Vaccine

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.vaccine.2015.07.003

    authors: DiazGranados CA,Dunning AJ,Robertson CA,Talbot HK,Landolfi V,Greenberg DP

    更新日期:2015-08-26 00:00:00

  • Influenza vaccination in a healthy geriatric population: preferential induction of antibodies specific for the H3N2 influenza strain despite equal T cell responsiveness to all vaccine strains.

    abstract::Cellular as well as humoral immune reactivity were studied in healthy young (< 30 years; n = 12) and older (> 65 years; n = 12) individuals before as well as 1 month after immunization with a trivalent whole virus influenza vaccine. Before vaccination, peripheral blood mononuclear cell proliferation in response to in ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(97)88329-6

    authors: Saurwein-Teissl M,Steger MM,Glück R,Cryz S,Grubeck-Loebenstein B

    更新日期:1998-01-01 00:00:00

  • Effect of hepatitis A vaccination schedules on immune response.

    abstract::An inactivated hepatitis A vaccine was given to 104 seronegative volunteers aged between 19 and 60 years according to two schedules: 0, 1 and 2 months or 0, 1 and 6 months. The vaccine was well tolerated and 97 and 100% of vaccinees developed a serum antibody response following a single and two doses of vaccine respec...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/0264-410x(92)90563-y

    authors: Tilzey AJ,Palmer SJ,Barrow S,Perry KR,Tyrell H,Safary A,Banatvala JE

    更新日期:1992-01-01 00:00:00

  • Perspectives on the control of hepatitis A by vaccination.

    abstract::The availability of an inactivated hepatitis A virus (HAV) vaccine, and the development of live attenuated virus vaccines against hepatitis represent great advances in the effort to control an important cause of viral hepatitis. There are a number of ways hepatitis A vaccines could be used, depending on the epidemiolo...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/0264-410x(92)90555-x

    authors: Kane MA

    更新日期:1992-01-01 00:00:00

  • Avian paramyxovirus serotypes 2-9 (APMV-2-9) vary in the ability to induce protective immunity in chickens against challenge with virulent Newcastle disease virus (APMV-1).

    abstract::The avian paramyxoviruses (APMVs) belong to the genus Avulavirus of family Paramyxoviridae. The APMVs are classified into nine serotypes on the basis of hemagglutination inhibition (HI) and neuraminidase inhibition (NI) assays, although some serologic cross-reaction exists. Newcastle disease virus (NDV), which constit...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.12.090

    authors: Nayak B,Dias FM,Kumar S,Paldurai A,Collins PL,Samal SK

    更新日期:2012-03-09 00:00:00

  • Comparative incidence dynamics and serotypes of meningitis, bacteremic pneumonia and other-IPD in young children in the PCV era: Insights from Israeli surveillance studies.

    abstract:INTRODUCTION:Widespread introduction of pneumococcal conjugated vaccines (PCVs) impacted on invasive pneumococcal disease (IPD). However, IPD reduction may not be similar in all outcomes within IPD. We assessed PCV7/PCV13 impact on pneumococcal meningitis, bacteremic pneumonia (BP) and other (non-meningitis, non-pneumo...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2017.05.059

    authors: Ben-Shimol S,Givon-Lavi N,Grisaru-Soen G,Megged O,Greenberg D,Dagan R,Israel Bacteremia and Meningitis Active Surveillance Group.

    更新日期:2018-08-28 00:00:00

  • Safety evaluation of a recombinant myxoma-RHDV virus inducing horizontal transmissible protection against myxomatosis and rabbit haemorrhagic disease.

    abstract::We have recently developed a transmissible vaccine to immunize rabbits against myxomatosis and rabbit haemorrhagic disease based on a recombinant myxoma virus (MV) expressing the rabbit haemorrhagic disease virus (RHDV) capsid protein [Bárcena et al. Horizontal transmissible protection against myxomatosis and rabbit h...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(00)00183-3

    authors: Torres JM,Ramírez MA,Morales M,Bárcena J,Vázquez B,Espuña E,Pagès-Manté A,Sánchez-Vizcaíno JM

    更新日期:2000-09-15 00:00:00

  • Nasopharyngeal carriage of Streptococcus pneumoniae and other bacteria in the 7th year after implementation of the pneumococcal conjugate vaccine in the Netherlands.

    abstract::After introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) in the infant national immunization program (NIP) in the Netherlands in 2006, Streptococcus pneumoniae strains of the non-vaccine serotype 19A emerged and became the dominant serotype in carriage in children and their parents. Similar patterns we...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2015.11.060

    authors: Bosch AATM,van Houten MA,Bruin JP,Wijmenga-Monsuur AJ,Trzciński K,Bogaert D,Rots NY,Sanders EAM

    更新日期:2016-01-20 00:00:00

  • Feline immunodeficiency virus (FIV) vaccine efficacy and FIV neutralizing antibodies.

    abstract::A HIV-1 tier system has been developed to categorize the various subtype viruses based on their sensitivity to vaccine-induced neutralizing antibodies (NAbs): tier 1 with greatest sensitivity, tier 2 being moderately sensitive, and tier 3 being the least sensitive to NAbs (Mascola et al., J Virol 2005; 79:10103-7). He...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2013.05.024

    authors: Coleman JK,Pu R,Martin MM,Noon-Song EN,Zwijnenberg R,Yamamoto JK

    更新日期:2014-02-03 00:00:00

  • Basic principle of population-based cohort study to evaluate influenza vaccine effectiveness among elderly Japanese.

    abstract::Influenza vaccines minimize the risk of influenza-related morbidity, complication, and death in elderly people. Although evaluating vaccine effectiveness (VE) is important for promoting immunization programs and coping with influenza epidemics, it is difficult to evaluate its effectiveness in Japan, where no framework...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2017.07.002

    authors: Hara M,Hirota Y

    更新日期:2017-08-24 00:00:00

  • Structural perturbation of diphtheria toxoid upon adsorption to aluminium hydroxide adjuvant.

    abstract::Aluminium-containing adjuvants are often used to enhance the potency of vaccines. In the present work we studied whether adsorption of diphtheria toxoid to colloidal aluminium hydroxide induces conformational changes of the antigen. Diphtheria toxoid has a high affinity for the aluminium hydroxide particles based on a...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.09.020

    authors: Régnier M,Metz B,Tilstra W,Hendriksen C,Jiskoot W,Norde W,Kersten G

    更新日期:2012-11-06 00:00:00